DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+13.41%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.21B
AUM Growth
+$2.21B
(+22%)
Cap. Flow
+$176M
Cap. Flow
% of AUM
7.94%
Top 10 Holdings %
Top 10 Hldgs %
38.16%
Holding
100
New
15
Increased
24
Reduced
25
Closed
9
Top Buys
| 1 |
McKesson
MCK
|
$63.5M |
| 2 |
DexCom
DXCM
|
$57.3M |
| 3 |
Viatris
VTRS
|
$56M |
| 4 |
Glaukos
GKOS
|
$53.9M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$46.5M |
Top Sells
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$73.6M |
| 2 |
Gilead Sciences
GILD
|
$66.4M |
| 3 |
NXTM
NxStage Medical Inc.
NXTM
|
$62.2M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$32.5M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$28M |
Sector Composition
| 1 | Healthcare | 76.44% |
| 2 | Financials | 0.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
| $150M | 6.74% | 1,547,386 -760,744 | -33% | -$73.6M |
|
|
2
McKesson
MCK
$85.4B
| $112M | 5.04% | 729,000 +413,583 | +131% | +$63.5M |
|
|
3
Viatris
VTRS
$12.3B
| $98.9M | 4.46% | 3,153,611 +1,786,492 | +131% | +$56M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $87.7M | 3.95% | 6,917,070 -2,081,343 | -23% | -$26.4M |
|
|
5
Glaukos
GKOS
$5.5B
| $83.4M | 3.76% | 2,527,032 +1,632,481 | +182% | +$53.9M |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $69.5M | 3.13% | 1,860,137 +681,532 | +58% | +$25.5M |
|
|
7
DexCom
DXCM
$29.5B
| $69.5M | 3.13% | 1,419,911 +1,172,070 | +473% | +$57.3M |
|
|
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $58.5M | 2.63% | 1,365,039 +1,085,287 | +388% | +$46.5M |
|
|
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
| $43.6M | 1.96% | 1,579,285 -2,254,045 | -59% | -$62.2M |
|
|
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
| $42.7M | 1.92% | 1,525,410 -203,858 | -12% | -$5.71M |
|
11
Editas Medicine
EDIT
$231M
| $41M | 1.85% | 1,709,400 | – | – |
|
12
Aclaris Therapeutics
ACRS
$209M
| $40.7M | 1.83% | 1,577,927 +1,202,927 | +321% | +$31M |
|
|
AVDL
13
Avadel Pharmaceuticals
AVDL
$1.43B
| $38.4M | 1.73% | 3,655,494 | – | – |
|
|
XENT
14
DELISTED
Intersect ENT, Inc
XENT
| $37.7M | 1.7% | 1,210,000 +20,423 | +2% | +$636K |
|
|
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $36.8M | 1.66% | 362,724 +2,741 | +0.8% | +$278K |
|
16
Ascendis Pharma
ASND
$11.8B
| $30.8M | 1.39% | 850,000 +430,547 | +103% | +$15.6M |
|
|
AERI
17
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $30.7M | 1.39% | 632,686 -328,461 | -34% | -$16M |
|
18
AnaptysBio
ANAB
$569M
| $28.8M | 1.3% | 824,338 +271,479 | +49% | +$9.49M |
|
19
Natera
NTRA
$23.1B
| $28.1M | 1.27% | +2,181,542 | New | +$28.1M |
|
|
DBVT
20
DBV Technologies
DBVT
$264M
| $27.8M | 1.25% | 655,897 -9,300 | -1% | -$395K |
|
21
Insulet
PODD
$23.9B
| $27.4M | 1.23% | +497,000 | New | +$27.4M |
|
|
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $27.3M | 1.23% | 1,072,329 +655,600 | +157% | +$16.7M |
|
|
LCI
23
DELISTED
Lannett Company, Inc.
LCI
| $26.8M | 1.21% | 1,453,259 -70,698 | -5% | -$1.3M |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| $26.1M | 1.17% | 4,975,451 +1,476,249 | +42% | +$7.74M |
|
|
XLRN
25
DELISTED
Acceleron Pharma Inc.
XLRN
| $23M | 1.03% | +615,000 | New | +$23M |
|